Catabasis Pharma (CATB) Stock Overview
NASDAQ:CATB -
CATB Key Statistics, Chart & Performance
The current stock price of CATB is 8.54 null. In the past month the price increased by 3.89%. In the past year, price decreased by -78.07%.
CATB Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 19.89 | 372.04B | ||
| AMGN | AMGEN INC | 13.47 | 158.13B | ||
| GILD | GILEAD SCIENCES INC | 14.83 | 142.41B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 23.32 | 101.30B | ||
| REGN | REGENERON PHARMACEUTICALS | 12.92 | 62.48B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 59.56B | ||
| ARGX | ARGENX SE - ADR | 71.2 | 40.39B | ||
| ONC | BEONE MEDICINES LTD-ADR | 6.35 | 37.29B | ||
| INSM | INSMED INC | N/A | 27.88B | ||
| BNTX | BIONTECH SE-ADR | N/A | 26.66B | ||
| NTRA | NATERA INC | N/A | 22.73B | ||
| BIIB | BIOGEN INC | 8.7 | 20.42B |
Related stock screener links
About CATB
Company Profile
Catabasis Pharmaceuticals Inc is a US-based company operating in Biotechnology industry. The company is headquartered in Boston, Massachusetts and currently employs 20 full-time employees. The company went IPO on 2015-06-25. Catabasis Pharmaceuticals, Inc. is a biopharmaceutical company. The firm is focused on development and commercialization of therapeutics. The firm's lead product candidate is QLS-215. QLS-215 is a monoclonal antibody designed to inhibit plasma kallikrein for the treatment of hereditary angioedema, or HAE, a rare, debilitating and life-threatening disease. Plasma kallikrein is a critical component of HAE that causes pathologic vascular permeability, vasodilation and excessive tissue swelling. The firm is in the preclinical development for QLS-215 and to initiate a Phase I a clinical trial.
Company Info
Catabasis Pharma
100 High Street, 28th Floor
Boston MASSACHUSETTS 02110 US
CEO: Jill C. Milne
Employees: 20
Phone: 16173491971.0
Catabasis Pharma / CATB FAQ
What is the stock price of Catabasis Pharma today?
The current stock price of CATB is 8.54 null. The price decreased by -6.97% in the last trading session.
What is the ticker symbol for Catabasis Pharma stock?
The exchange symbol of Catabasis Pharma is CATB and it is listed on the Nasdaq exchange.
On which exchange is CATB stock listed?
CATB stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for Catabasis Pharma stock?
4 analysts have analysed CATB and the average price target is 24.23 null. This implies a price increase of 183.67% is expected in the next year compared to the current price of 8.54. Check the Catabasis Pharma stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is Catabasis Pharma worth?
Catabasis Pharma (CATB) has a market capitalization of 33.34M null. This makes CATB a Nano Cap stock.
How many employees does Catabasis Pharma have?
Catabasis Pharma (CATB) currently has 20 employees.
What are the support and resistance levels for Catabasis Pharma (CATB) stock?
Catabasis Pharma (CATB) has a resistance level at 9.54. Check the full technical report for a detailed analysis of CATB support and resistance levels.
Should I buy Catabasis Pharma (CATB) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of CATB, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of CATB, evaluating the profitability, health, valuation and growth aspects
- Catabasis Pharma (CATB) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- Catabasis Pharma (CATB) Sales and EPS estimates to see what analysts future expectations are.
- Catabasis Pharma (CATB) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- Catabasis Pharma (CATB) Insider and Institutional Ownership to learn about the owners and their transactions.
- Catabasis Pharma (CATB) Stock Chart to make your own analysis
- Catabasis Pharma (CATB) Latest news and press-releases to stay up to date.
Does Catabasis Pharma (CATB) stock pay dividends?
CATB does not pay a dividend.
What is the Price/Earnings (PE) ratio of Catabasis Pharma (CATB)?
Catabasis Pharma (CATB) does not have a PE ratio as the earnings reported over the last twelve months were negative (-5.9).
CATB Technical Analysis
ChartMill assigns a technical rating of 1 / 10 to CATB. When comparing the yearly performance of all stocks, CATB is a bad performer in the overall market: 99.04% of all stocks are doing better.
CATB Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to CATB. CATB scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages.
CATB Financial Highlights
Over the last trailing twelve months CATB reported a non-GAAP Earnings per Share(EPS) of -5.9. The EPS decreased by -175.7% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -140.05% | ||
| ROE | N/A | ||
| Debt/Equity | 0 |
CATB Forecast & Estimates
4 analysts have analysed CATB and the average price target is 24.23 null. This implies a price increase of 183.67% is expected in the next year compared to the current price of 8.54.